Rhodiola crenulata sourced vesicle with Alzheimer's disease resisting effect as well as preparation method and application of rhodiola crenulata sourced vesicle

The large Rhodiola vesicles (VRC) prepared by differential-ultracentrifugation solves the problems of low extraction efficiency and difficulty in quality control. It is found that it has significant efficacy for Alzheimer's disease, interfering with NF-κB and MAPK Signaling pathways, which improve neuroinflammatory and oxidative stress, provide a safe and efficient AD treatment plan.

CN118903238APending Publication Date: 2024-11-08SHENYANG PHARMA UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411029658.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

When developing anti-Alzheimer's drugs, the prior art mainly targets single-consistent disease targets, with limited effects, and low extraction efficiency and difficulty in quality control of plant-derived exosome-like nanovesicles, which limit their in AD Application in treatment.

Method used

Velves from Rhodiola (VRC) were prepared by differential-ultracentrifugation combined with sucrose density gradient centrifugation method, and analyzed its chemical composition, lipids, proteins and RNA, and found that it was used to analyze Alzheimer's. The disease has a pharmacokinetic effect, interfering with the NF-κB and MAPK signaling pathways to treat AD.

Benefits of technology

VRC has shown significant efficacy in Alzheimer's disease, improving neuroinflammatory, oxidative stress and apoptosis, and is safe and does not produce adverse reactions, which has high commercial value and social significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903238A_ABST
    Figure CN118903238A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and particularly relates to a rhodiola crenulata-sourced vesicle (VRC) with an effect of resisting Alzheimer's disease (AD) as well as a preparation method and application of the rhodiola crenulata-sourced vesicle (VRC). It is found for the first time that VRC has remarkable prevention and treatment effects on AD, is safe to use and does not generate adverse reactions, and therefore VRC is an ideal candidate developed into the medicine for preventing or treating AD and has high commercial value and social significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and in particular relates to a vesicle (VRC) derived from Rhodiola rosea with anti-Alzheimer's disease (AD) effect, and a preparation method and use thereof. Background Art

[0002] Extracellular vesicles (EVs) are nanoscale vesicles with membrane structures that can be peeled off or secreted from the cell membrane by almost all living cells. According to their diameters, EVs are usually divided into exosomes, microvesicles, and apoptotic bodies. Exosomes are the most typical EVs in mammals, which can carry metabolites, proteins, lipids, mRNA, and miRNA. To date, a variety of EVs produced by human cells have been isolated, and their biological functions of mediating intercellular communication and regulating pathological processes have gradually been revealed. In addition, because EVs have clear pharmacological functions, good biocompatibility, specific tissue targeting, and excellent drug loading capacity, they are widely considered to be a promising therapeutic drug and drug delivery carrier.

[0003] There is increasing evidence that plant-derived exosomes-like nanovesicles (PDENs) can be absorbed by the mammalian gastrointestinal tract and have the potential to regulate intercellular communication between humans and plants. In recent years, more and more studies have discovered and reported the presence of PDENs in vegetables, fruits, and medicinal plants, such as grapes, grapefruit, ginger, lemon, broccoli, carrots, purslane, bone drynaria, rhodiola, ginseng, rehmannia, catharanthus roseus, yellow lacquer wood, and atractylodes. Compared with artificial nanoparticles, PDENs have advantages such as natural molecular transport properties, lower immunogenicity and toxic side effects. Therefore, PDENs have greater potential for drug delivery. Recent studies have found that PDENs carry miRNA and anticancer compounds for targeted treatment of brain diseases, indicating that they have the advantage of crossing biological barriers. In addition, some studies have shown that the drug delivery strategy of animal exosomes may cause potential biological hazards, such as stimulating tumor proliferation, while plant-derived exosome-like nanovesicles have a lower risk of biological hazards and are more economically feasible as drug carriers. In addition, methods to optimize the extraction process and improve the extraction efficiency are also being explored. Ultracentrifugation is still the main method for isolating plant-derived exosome-like nanovesicles, but its extraction efficiency is low. Intact plants contain a large number of nanovesicle subpopulations from different tissue parts, which may have different structures and functions. Plant-derived exosome-like nanovesicles from different species have more diverse components and biodistribution characteristics. This high heterogeneity limits the quality control of PDENs and further industrial production. Therefore, it is necessary to systematically study the important pharmacological properties of PDENs, such as composition, stability, biocompatibility, and biodistribution characteristics. Although the current research on PDENs is not comprehensive enough, PDENs have good biocompatibility and the advantages of wide sources, low price, and easy access, and are considered to be a bio-nanomaterial with great development potential. At present, the understanding of plant-derived exosome-like nanovesicles is still in its infancy, and its pharmacological application faces many challenges.

[0004] As the problem of global population aging becomes increasingly prominent, the prevalence of Alzheimer's disease (AD) has increased year by year and has become a serious public health problem. AD ​​is a common neurodegenerative disease characterized by reactive astrocyte proliferation and microgliosis, extensive synaptic dysfunction and neuronal degeneration, memory loss, significant decline in cognitive ability, language and emotional disorders, slow thinking and personality changes. AD is a common disease of the elderly. According to statistics, there are currently about 55.2 million people suffering from the disease worldwide, and there are 10 million AD patients over the age of 60 in my country, which puts families and society under tremendous mental and economic pressure. Therefore, AD has become a burden on the global public and healthcare systems. The pathogenesis of AD is complex and affected by multiple factors, and its pathogenesis has not yet been clarified. The neuropathological characteristics of AD patients include intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated Tau protein, extracellular amyloid plaques formed by Aβ, and primary neuronal necrosis. Current evidence shows that the pathological manifestations of Aβ deposition precede the onset of clinical symptoms, and the formation of NFTs leads to neuronal damage and the onset of AD. There are many hypotheses about the pathogenesis of AD: β-amyloid protein deposition, abnormal phosphorylation of Tau protein, cholinergic system disorder, neuroinflammation, mitochondrial dysfunction, oxidative stress, free radical damage, cell apoptosis, autophagy, blood-brain barrier dysfunction, changes in the intestinal microbiome, etc.

[0005] As the prevalence of AD increases year by year, the development of effective drugs and therapies for the disease has become an important challenge. At present, the treatment methods for AD mainly include drug therapy, gene therapy and stem cell therapy. During the occurrence of AD, the partial death of cholinergic neurons will cause a decrease in acetylcholine produced by the cholinergic transmission system, resulting in impaired learning and memory functions. Therefore, cholinesterase inhibitors, such as donepezil, rivastigmine, rivastigmine and galantamine, have been clinically used in patients with mild to moderate AD to block the decomposition of acetylcholine. In addition, N-methyl D-aspartate (NMDA) receptor disorders can also lead to neuronal death, so NMDA receptor antagonists, such as memantine, provide another option for treating moderate to severe AD patients. In addition to drugs that inhibit neuronal death, monoclonal antibodies (lencanetumab), free radical scavenging and antioxidant drugs, immune system regulation drugs, etc. can also be used in the clinical treatment of AD. However, although current AD clinical drugs are beneficial in improving and stabilizing symptoms, they mainly prevent or treat a single pathogenic target of AD, and can only alleviate symptoms such as cognitive impairment caused by AD for a limited period of time, but will not stop or reverse neuronal death. Therefore, finding more ideal drugs and therapies for the prevention and treatment of AD has become one of the hot topics in AD research.

[0006] Rhodiola rosea is the dried root and rhizome of Rhodiola crenulata (Hook.f.et Thoms.) H.Ohba, a plant of the genus Rhodiola in the Crassulaceae family, and is included in the "Chinese Pharmacopoeia" (2020 edition). Its rhizomes are usually dug up after the flower stems wither in autumn. The rhizomes are cylindrical, slightly curved, sometimes with branches, orange-red or purple-red in cross section, light and loose in texture, with an aromatic smell, slightly bitter taste, and sweet aftertaste. Rhodiola rosea is believed to have the effects of invigorating qi and activating blood circulation, unblocking meridians and relieving asthma. In traditional Chinese medicine, it is often used to treat symptoms such as qi deficiency and blood stasis, chest pain, hemiplegia due to stroke, fatigue and asthma. Various plants of the genus Rhodiola mainly grow in mountainous areas at high latitudes and altitudes in the northern hemisphere, distributed in Europe, North America, Arctic Asia and other places, especially in rocks, glaciers, shrubs and other places at an altitude of 4000-5600 meters. In my country, Rhodiola rosea is mainly distributed in high-altitude cold regions such as Tibet, Sichuan, Yunnan and Qinghai. Rhodiola rosea is a commonly used medicinal and edible plant with high medicinal value and a long history. As early as 2,000 years ago, it was used as a commonly used medicinal material in Tibetan medicine. Its Tibetan name is "Solo Mabu" and it was first recorded in the Tibetan medicine classic "Four Pharmacopoeias". In the "Qianjin Yifang" by Sun Simiao in the Tang Dynasty, it was recorded that "Sedum rosea has a bitter, sour and flat taste and is non-toxic. It can clear the body and brighten the eyes. Long-term use can make the mind immortal." It enjoys the reputation of "Oriental Magic Grass".

[0007] The chemical components of Rhodiola rosea include alcohols and their glycosides, flavonoids and their glycosides, organic acids and their derivatives, terpenes, volatile oils, coumarins, steroids, etc. These components give it a wide range of pharmacological effects, including antioxidant, anti-fibrotic, anti-inflammatory, immunomodulatory, anti-aging, anti-fatigue, anti-hypoxia, anti-tumor, and cardiovascular protection. Studies have shown that in the rat atherosclerosis model, Rhodiola rosea proanthocyanidins improve atherosclerosis by regulating lipid metabolism, restoring antioxidant capacity, inhibiting the release of proinflammatory cytokines and chemotactic cytokines, and regulating endothelial dysfunction. In summary, Rhodiola rosea plays an important role in traditional Chinese medicine, and its diverse pharmacological effects have attracted widespread attention in scientific research.

[0008] The present invention prepares, purifies and characterizes vesicles derived from Rhodiola crenulate (VRC) for the first time, and analyzes and identifies the chemical components, lipids, proteins and RNA of VRC. The VRC obtained by the present invention does not contain the effective ingredients of traditional Rhodiola rosea extracts (e.g., tyrosol, salidroside, salidroside, epicatechin, ethyl gallate, etc.). The present invention discovers for the first time that VRC has a certain pharmacodynamic effect on AD, and discovers the mechanism by which VRC treats AD by interfering with NF-κB and MAPK signaling pathways.

[0009] VRC in the present invention also includes Rhodiola rosea vesicles, Rhodiola rosea EVs, Rhodiola rosea vesicle-like nanoparticles, Rhodiola rosea exosome-like nanoparticles, Rhodiola rosea exosome-like nanovesicles, Rhodiola rosea extracellular vesicles, Rhodiola rosea extracellular vesicle-like particles, Rhodiola rosea extracellular vesicle-like nanoparticles, etc.; Rhodiola rosea can also be called Rhodiola source, such as Rhodiola-derived vesicle-like particles, Rhodiola-derived EVs, etc. Summary of the invention

[0010] In view of the above situation, in order to solve the defects of the prior art, the present invention provides VRC with anti-AD effect and its preparation method and use.

[0011] To achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0012] In a first aspect, the present invention provides a composition for preventing or treating AD, the composition comprising VRC.

[0013] Preferably, the VRC is nanoscale.

[0014] As an optional mode, in the above composition, the VRC comprises one or more of the following: exosomes, apoptotic bodies, microvesicles, lysosomes, endosomes, lipoproteins or cell-derived nanoparticles.

[0015] Preferably, the particle size of the VRC is 50-1000 nm.

[0016] As an optional manner, in the above composition, the VRC has a double-membrane structure under a transmission electron microscope, mostly in the shape of a concave round cake, and the particle size of the VRC is 50-300 nm.

[0017] As an optional mode, in the above composition, the VRC mainly contains lipid components, protein components, and nucleic acid components, and contains no or very little traditional Rhodiola rosea medicinal ingredients.

[0018] Preferably, in terms of mass percentage, the medicinal ingredients of the traditional Rhodiola rosea account for less than 5% of the total mass of the VRC.

[0019] More preferably, the traditional Rhodiola rosea medicinal ingredients are selected from one or more of the following: tyrosol, salidroside, salidroside, epicatechin or ethyl gallate.

[0020] Preferably, in terms of mass percentage, the VRC mainly contains 50%-95% lipid component, 5-50% protein component, and <5% nucleic acid component.

[0021] In addition, preferably, the composition does not contain traditional Rhodiola rosea medicinal ingredients.

[0022] As an optional method, in the above composition, the VRC is prepared by differential-ultracentrifugation combined with sucrose density gradient centrifugation to obtain purer VRC, which comprises the following steps: taking an appropriate amount of Rhodiola rosea medicinal material, soaking it in PBS and then breaking it with a wall-breaking machine, filtering to remove residues, using differential centrifugation, differential centrifugation in sequence, centrifuging at 1000×g for 10 min, 3000×g for 20 min, and 5000×g for 30 min, taking the supernatant, passing it through a 0.8 μm filter membrane, and purifying it by sucrose density gradient (using 10%, 30%, 45% and 55% [w / v, g / mL] in sequence), ultracentrifuging at 150,000×g for 70 min at 4°C, and collecting 10%-30% and 30%-45% bands, which are VRC samples.

[0023] As an optional manner, in the above composition, the VRC primary product can be prepared by a differential centrifugation plus sedimentation method, an ultrafiltration method, or a kit extraction method, and then purified by at least one of density gradient centrifugation, column chromatography, ultrafiltration, etc. to obtain relatively pure VRC, and the quantitative VRC is stored at -80°C.

[0024] As an optional mode, in the above-mentioned composition, the composition may also contain other clinically commonly used drugs for preventing or treating AD, and the other clinically commonly used drugs for preventing or treating AD are selected from one or more of the following: cholinesterase inhibitors (such as donepezil hydrochloride tablets, rivastigmine bitartrate capsules, galantamine hydrobromide tablets), glutamate receptor antagonists (such as memantine hydrochloride tablets) and other types of drugs (such as ganlutena capsules).

[0025] In a second aspect, the present invention provides a pharmaceutical preparation having the function of preventing or treating AD, wherein the pharmaceutical preparation comprises the composition described in the first aspect above, and a pharmaceutically acceptable carrier.

[0026] As an optional mode, in the above-mentioned pharmaceutical preparation, the pharmaceutical preparation is an oral preparation, an injection or a rectal preparation.

[0027] Preferably, the oral preparation is selected from oral liquid, tablet, powder, capsule or granule.

[0028] In a third aspect, the present invention provides use of the composition described in the first aspect or the pharmaceutical preparation described in the second aspect in the preparation of a drug for preventing or treating AD.

[0029] As an optional mode, in the above-mentioned use, the AD is manifested as memory loss, language and emotional disorders, slow thinking and personality changes.

[0030] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] (1) The present invention prepares, purifies and characterizes VRC for the first time, and analyzes and identifies the chemical components, lipids, proteins and RNA of VRC. The results show that VRC contains no or very little chemical components in traditional Rhodiola rosea extracts (e.g., tyrosol, salidroside, salidroside, epicatechin, ethyl gallate, etc.), reveals the material composition and category of VRC, and obtains natural active ingredients such as lipid components, proteins, and miRNA. The present invention establishes Aβ 25-35 The induced AD-related PC12 cell model was established and it was demonstrated that VRC could improve neuroinflammation, oxidative stress and cell apoptosis, revealing its anti-AD pharmacodynamic effect and laying the foundation for the study of the mechanism of action of VRC in treating AD.

[0033] (2) The VRC of the present invention is safe to use and does not produce adverse reactions. Therefore, VRC is an ideal candidate for developing a drug for preventing or treating AD and has high commercial value and social significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 : Appearance of VRC samples prepared by differential-ultracentrifugation combined with sucrose density gradient centrifugation in the examples.

[0035] Figure 2 : Transmission electron microscope image (TEM) of VRC in the embodiment.

[0036] Figure 3 : Particle size distribution of VRC in the examples.

[0037] Figure 4 : Zeta potential distribution of VRC in the embodiment.

[0038] Figure 5 : The proportion of various lipid components in VRC in the embodiment.

[0039] Figure 6 : Identification results of protein components in VRC in the examples.

[0040] Figure 7 : The proportion of various Small RNAs in VRC in the embodiment.

[0041] Figure 8: Screening of the concentrations of RC group and VRC group by MTT method in the embodiment. Wherein, A is RC group and B is VRC group.

[0042] Fig. 9 : Screening of DHCL concentration in the positive drug group by MTT method in the embodiment.

[0043] Fig.10 : In the embodiment, the MTT method was used to detect the cell viability of each group.

[0044] Fig.11 : The effects of each group in the example on TNF-α, IL-1β and IL-6 inflammatory factors in AD model PC12 cells.

[0045] Fig.12 :The effects of each group in the embodiment on the oxidative stress indicators GSH-Px and MDA of AD model PC12 cells. Wherein, A is the content of GSH-Px, and B is the content of MDA.

[0046] Fig.13 : The influence of each group in the embodiment on the content of ROS, an oxidative stress indicator of AD model PC12 cells.

[0047] Fig.14 : The improvement of apoptosis of PC12 cells in each group of the embodiment on AD model. Wherein, A is Hoechst 33342 staining, and B is cell apoptosis rate. DETAILED DESCRIPTION

[0048] In order to facilitate the understanding of those skilled in the art, some components involved in the present invention are further described below.

[0049] As used herein, the dosage form of the product of the present invention is powder, tablet, capsule, granule or oral solution. Preferably, the dosage form of the present invention is powder or capsule.

[0050] As used herein, the product of the present invention may also include "an acceptable carrier in the field of pharmacy, functional food or health care products", which refers to a conventional carrier in the above-mentioned technical field, selected from one or more of fillers, binders, disintegrants, lubricants, suspending agents, wetting agents, pigments, flavoring agents, solvents, and surfactants.

[0051] The filler of the present invention includes but is not limited to starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, glucose, etc.; the lubricant includes but is not limited to magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxamer, etc.; the binder includes but is not limited to water, ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the disintegrant includes but is not limited to starch effervescent mixture, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the suspending agent includes but is not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ether and carboxymethyl chitosan, etc.; the solvent includes but is not limited to water, a balanced salt solution, etc.

[0052] Preferably, the product of the present invention can be made into various solid oral preparations, liquid oral preparations, etc. Acceptable oral solid preparations include: powders, ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, dripping pills, powders, etc., and oral liquid preparations include oral liquids, emulsions, etc.

[0053] The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.

[0054] In the above-mentioned uses, the application time, number of applications, and frequency of application of various active ingredients need to be determined according to the actual conditions of the subject, which is within the technical scope of those skilled in the art. For example, when the treatment regimen for mice or rats is applied to humans, the effective doses of all active ingredients for humans can be converted by their effective doses for mice or rats, which is also easy to achieve for those of ordinary skill in the art.

[0055] The preferred embodiments of the present invention are described below. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention and are not intended to limit the present invention. If specific techniques or conditions are not specified in the embodiments, the techniques or conditions described in the literature in this area or the product instructions are used. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0056] Example:

[0057] 1.1 Preparation, purification and characterization of VRC

[0058] 1.1.1 Preparation and purification of VRC

[0059] VRC is prepared by differential-ultracentrifugation combined with sucrose density gradient centrifugation to obtain purer VRC, which includes the following steps: 290 g of Rhodiola rosea is soaked in PBS and then crushed with a wall-breaking machine, filtered to remove residues, and differential centrifugation is performed in sequence, centrifuged at 1000×g for 10 min, 3000×g for 20 min, and 5000×g for 30 min, the supernatant is taken, and after passing through a 0.8 μm filter membrane, it is purified by sucrose density gradient (using 10%, 30%, 45%, 55% and 55% in sequence, [w / v, g / mL]), ultracentrifuged at 150000×g for 70 min at 4°C, and the 10%-30% and 30%-45% bands are collected as VRC samples. The results are as follows: Figure 1 .

[0060] 1.1.2 Morphological and structural characterization of VRC

[0061] (1) VRC transmission electron microscopy characterization

[0062] Take out 10 μL of VRC sample. Pipette 10 μL of sample and drop it on the copper mesh to precipitate for 1 minute, remove the floating liquid with filter paper, and drop 10 μL of uranyl acetate on the copper mesh to precipitate for 1 minute, remove the floating liquid with filter paper. After drying at room temperature for several minutes, perform electron microscopy detection and imaging at 100 kV to obtain transmission electron microscopy imaging results. Transmission electron microscopy (TEM) observed that the exosome morphology is saucer-shaped, which is a nanovesicle with a double-layer membrane structure. Its particle size is mainly distributed in the range of 80-400 nm. The results are as follows Figure 2 .

[0063] (2) NTA particle size analysis of VRC

[0064] Take out an appropriate amount of VRC sample and dilute it to a suitable multiple. After the instrument performance test is qualified by the standard sample, the exosome sample is loaded to obtain the particle size and concentration information of VRC detected by the instrument.

[0065] The average particle size of VRC was 81.1 nm using NTA particle size analysis, which was close to that detected by TEM and within the appropriate range. The particle concentration was 3.73×10 10 Particles / mL, see Figure 3 .

[0066] (3) Zeta potential analysis of VRC

[0067] The VRC prepared in the above section 1.1 was subjected to Zeta potential analysis. The particle size analyzer results showed that the Zeta potential of VRC was unimodal, with an average potential distribution of -34.2±7.09mV. The results are as follows: Figure 4 As shown, it shows that the surface of the obtained VRC has a negative charge and the system is relatively stable.

[0068] 1.2 Identification of small molecule chemical components, lipid components, protein components and small RNA in VRC

[0069] 1.2.1 Detection and analysis of small molecule chemical components and lipid components in VRC

[0070] The small molecule chemical components of VRC were analyzed using liquid chromatography-mass spectrometry (Agilent 1100 series liquid chromatograph coupled with Solarix 7.0TFT-ICR MS instrument). Based on the chromatographic retention behavior, primary precise molecular weight and molecular formula predicted by DataAnalysis software of each component, and compared with literature and databases, no relevant chemical components of Rhodiola rosea were found in VRC.

[0071] The analysis method combining RPLC-QTOF MS and HILIC-QTOF MS was used to conduct a more comprehensive and in-depth analysis of lipid fractions and qualitatively characterize the lipid components of VRC. Finally, a total of 67 lipid components were characterized in the VRC extract, including 45 fatty acyl components, 14 sphingolipid components, 3 glyceride components, 3 polyketide components, and 2 sterol components. For more information, see Figure 5 .

[0072] 1.2.2 Identification of protein components in VRC

[0073] The proteins in VRC were identified by the liquid chromatography-mass spectrometry system of UltiMate 3000RSLCnano liquid phase tandem Q Exactive HF mass spectrometer. The data were matched with reference to the Uniprot database. The number of mass spectra (MS / MS) spectra obtained was 18. A total of 8 peptides were identified through spectrum analysis, including 8 specific peptides. A total of 7 proteins were identified in this study, of which 5 were quantifiable. The results are shown in Figure 6 .

[0074] 1.2.3 Small RNA sequencing in VRC

[0075] Illumina HiSeq high-throughput sequencing technology (miRNA-seq) was used for sequencing. The Small RNA obtained after sequencing was annotated, analyzed, and screened using known databases to complete the identification of Small RNA, and obtain the statistical results of read length distribution and the proportion of each type of Small RNA. Small RNA was identified by sequencing and divided into five categories, namely miRNA, tRNA, rRNA, snRNA and other-ncRNA. The proportion of each type of Small RNA is as follows: Figure 7 As shown, a total of 69 miRNAs were identified.

[0076] 1.3 Preliminary study on the pharmacodynamic effects of VRC on PC12 cells, a model of Alzheimer's disease 1.3.1 Establishment and evaluation of the cell model

[0077] Take the poorly differentiated PC12 cells and culture them in an incubator at 37°C and 5% CO2 using RPMI-1640 medium containing 10% fetal bovine serum (FBS). Grow the cells to a density of about 90% and wash them once with PBS. Carefully discard the supernatant and add an appropriate volume of trypsin to digest the cells. When the cells become round, add fetal bovine serum to terminate the reaction. Use a 1mL pipette tip to blow the cells everywhere in the cell culture plate, collect the mixture into a 15mL centrifuge tube, and centrifuge at 90×g for 3 minutes. Carefully discard the supernatant and add 10 cells per well. 4 PC12 cells were seeded in a 96-well plate at a density of 100 μL per well. The plates were placed in a 37°C, 5% CO2 incubator for static culture. The culture medium was replaced once after 24 hours, and the cell morphology was observed under an inverted microscope. 25-35 (Abcam, UK) was dissolved in deionized distilled water, incubated at 37°C for 24 h, and diluted with RPMI-1640 medium before use.

[0078] The cell experiment was divided into the following groups, with 5 replicate wells in each group:

[0079] (1) Blank control group: cells were cultured normally with RPMI-1640 medium.

[0080] (2) Model group: 30 μM concentration of Aβ 25-35 The cells were treated with 5% paraformaldehyde (5% paraformaldehyde) (diluted with RPMI-1640 medium) and incubated for 24 h.

[0081] (3) Positive control group: Donepezil hydrochloride (DHCL) group: 30 μM Aβ 25-35 The cells were treated with different concentrations of DHCL (40, 50, 60 mM, diluted in RPMI-1640 medium) to screen the appropriate DHCL concentration.

[0082] (4) Treatment group (VRC group): Add 30 μM Aβ 25-35 And a series of concentrations of VRC solution (1×10 7 , 5×10 7 , 1×10 8 , 5×10 8 , 1×10 9 , 5×10 9 , 1×10 10Particles / mL, diluted in RPMI-1640 medium) to screen the appropriate VRC concentration. Rhodiola rosea extract group (RC group): 30 μM Aβ 25-35 And a series of RC solutions (6.25 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL, diluted in RPMI-1640 medium) were prepared to screen the appropriate RC concentration.

[0083] 1.3.2 Data Statistical Analysis

[0084] SPSS21.0 and GraphPadPrism 9.2.0 statistical software were used to perform Student's t-test and one-way ANOVA on the experimental data. The significance level was α = 0.05, that is, P < 0.05 indicated a significant difference, and P < 0.01, P < 0.001 and P < 0.0001 were considered to have very significant differences.

[0085] 1.3.3MTT cell viability assay

[0086] The MTT method was used to detect the effects of different concentrations of RC solution (6.25 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL) on Aβ 25-35 The cell viability of PC12 cells induced by RC was the highest when the concentration was 25 μg / mL (P<0.001). Figure 8 A, so this concentration was selected for subsequent experiments; MTT method was used to detect different concentrations of VRC solution (1×10 7 , 5×10 7 , 1×10 8 , 5×10 8 , 1×10 9 , 5×10 9 , 1×10 10 particles / mL) to Aβ 25-35 Induced cell viability of PC12 cells, such as Figure 8 As shown in B, as the VRC concentration increased to 5×10 9 The PC12 cell viability showed a gradual increasing trend (P<0.001), and when the VRC concentration reached 1×10 10 When the concentration of VRC was 5×10 particles / mL, the cell viability was reduced (P<0.01), so the treatment concentration of VRC was selected as 5×10 9Particles / mL. The cell viability of the positive control drug DHCL group was also significantly increased (P<0.01, P<0.01, P<0.0001) ( Fig. 9 ), choose a medium dose of 50mM DHCL. Fig.10 As shown in the figure, compared with the model group, the cell viability of the positive control drug DHCL group, RC group, and VRC group increased, and the VRC group (P<0.001) had more significant cell viability than the RC group (P<0.01), indicating that the VRC group had a better regulatory effect on the cell viability of the AD model. 1.3.4 Regulatory effect of VRC on inflammatory factors in PC12 cells of AD model

[0087] The regulatory effects of VRC on inflammatory factors such as TNF-α, IL-1β and IL-6 were investigated. Fig.11 As shown, each group could significantly reduce Aβ 25-35 The contents of TNF-α, IL-1β, and IL-6 in PC12 cells induced by Aβ were significantly increased in the model group (P<0.0001). Compared with the blank control group, the expression levels of TNF-α, IL-1β, and IL-6 in PC12 cells in the model group were significantly increased (P<0.0001); compared with the model group, the expression levels of TNF-α, IL-1β, and IL-6 in the DHCL group, RC group, and VRC group were significantly reduced (P<0.0001). The results showed that the VRC group could attenuate the expression of Aβ in PC12 cells. 25-35 Caused by upregulation of inflammatory factors such as TNF-α, IL-1β and IL-6.

[0088] 1.3.5 VRC improves oxidative stress in AD model PC12 cells

[0089] The improvement effect of VRC on oxidative stress indicators was investigated. The results of various indicators are as follows Fig.12 As shown in the results, compared with the blank control group, the content of MDA in PC12 cells in the model group increased significantly, while the activity of GSH-Px decreased significantly (P<0.0001); compared with the model group, the VRC group decreased the content of MDA (P<0.0001) and increased the activity of GSH-Px (P<0.0001), which alleviated the oxidative stress response. The effects of the RC group and the DHCL group on MDA and GSH-Px were similar to those of the VRC group. Compared with the blank control group, the content of ROS in PC12 cells in the model group increased significantly, and compared with the model group, the VRC group decreased the content of ROS (P<0.001). Immunofluorescence results showed that the VRC group could make Aβ 25-35 The content of ROS in PC12 cells induced by Fig.13 ). The results showed that the VRC group could inhibit the levels of ROS and MDA, increase the activity of GSH-Px, and inhibit the oxidative stress response, thus exerting its neuroprotective effect.

[0090] 1.3.6 VRC improves apoptosis in PC12 cells, an AD model

[0091] PC12 (poorly differentiated) cells were stained with Hoechst 33342 and photographed under a fluorescence microscope. Fig.14 As shown in A, in the blank control group, the PC12 cell nuclei were round and did not aggregate, indicating that the cells did not undergo apoptosis. 25-35 After treatment, the apoptosis rate of PC12 cells increased to 35.8% (P<0.0001), and some cell nuclei were found to be crescent-shaped and bright blue fluorescent fragments after fluorescence photography. After treatment with DHCL, RC and VRC, the apoptosis rates of PC12 cells decreased to 8.33%, 15.79% and 9.0%, respectively (P<0.0001). Fig.14 B. The results showed that the VRC group could improve Aβ 25-35 Induced apoptosis of PC12 cells.

[0092] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A composition for preventing or treating Alzheimer's disease (AD), characterized in that: The composition at least comprises vesicles (VRC) derived from Rhodiola rosea. Preferably, the VRC is nanoscale.

2. The composition according to claim 1, characterized in that: The VRC includes one or more of the following: exosomes, apoptotic bodies, microvesicles, lysosomes, endosomes, lipoproteins or cell-derived nanoparticles, and the particle size of the VRC is 50-1000 nm.

3. The composition according to claim 2, characterized in that: The VRC has a double-membrane structure under a transmission electron microscope, and is mostly in the shape of a concave round cake. The particle size of the VRC is 50-300 nm.

4. The composition according to claim 1, characterized in that: The VRC mainly contains lipid components, protein components, and nucleic acid components, and contains no or very little traditional Rhodiola rosea medicinal ingredients. Preferably, in terms of mass percentage, the traditional Rhodiola rosea medicinal ingredients account for less than 5% of the total mass of the VRC. More preferably, the traditional Rhodiola rosea medicinal ingredients are selected from one or more of the following: tyrosol, salidroside, salidroside, epicatechin or ethyl gallate.

5. The composition according to claim 1, characterized in that: The composition also contains other clinically commonly used drugs for preventing or treating AD, and the other clinically commonly used drugs for preventing or treating AD are selected from one or more of the following: cholinesterase inhibitors (such as donepezil hydrochloride tablets, rivastigmine bitartrate capsules, galantamine hydrobromide tablets), glutamate receptor antagonists (such as memantine hydrochloride tablets) and other types of drugs (such as ganlutena capsules).

6. A pharmaceutical preparation for preventing or treating AD, characterized in that: The pharmaceutical preparation comprises the composition according to any one of claims 1 to 5, and a pharmaceutically acceptable carrier.

7. The pharmaceutical preparation according to claim 6, characterized in that: The pharmaceutical preparation is an oral preparation, an injection or a rectal preparation. Preferably, the oral preparation is selected from oral liquid, tablet, powder, capsule or granule.

8. Use of the composition according to any one of claims 1 to 5 or the pharmaceutical preparation according to claim 6 or claim 7 in the preparation of a medicament for preventing or treating AD.

9. The use according to claim 8, characterized in that: The AD is manifested by memory loss, language and emotional disorders, slow thinking and personality changes.

Citation Information

Patent Citations

  • Plant exosome microcapsule embedded freeze-dried powder and preparation method thereof

    CN112352951A

  • Plant exosome microcapsule embedded freeze-dried powder

    CN114009772A

  • Plant-derived cell vesicle-like particles with anti-liver-injury effect and application of plant-derived cell vesicle-like particles

    CN118286295A

  • Stable non-aqueous compositions of plants extracts and methods of making the same

    US20230081296A1

  • Oral compositions of plants through a double extraction system and methods of making the same

    US20230149829A1